Lyell completes LYL273 manufacturing transfer to LyFE; Phase 1/2 data and FDA meeting expected 2027

Lyell Immunopharma, Inc.

Completed technology transfer of LYL273 to LyFE Manufacturing Center in Bothell, WA after FDA review of improved process and analytical methods.
Phase 1/2 trial in relapsed/refractory metastatic colorectal cancer continues enrolling; goal to determine recommended Phase 2 dose and safety plan.
Additional clinical data and End-of-Phase 1 meeting with FDA now expected in 2027.
CEO Lynn Seely notes encouraging clinical activity data and activation of additional clinical sites for expansion phase.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.